Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Strunk

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
European Heart Journal|July 25, 2008
NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitusMartin Huelsmann, Stephanie Neuhold, Guido Strunk, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 30, 2022
Malnutrition outweighs the effect of the obesity paradoxSuriya Prausmüller, Gregor Heitzinger, Noemi Pavo, et al.
European Journal of Clinical Investigation|June 16, 2010
Electrical optimization of cardiac resynchronization in chronic heart failure is associated with improved clinical long-term outcomeChristopher Adlbrecht, Martin Hülsmann, Marianne Gwechenberger, et al.
Diabetes Care|July 1, 2009
Endothelial markers may link kidney function to cardiovascular events in type 2 diabetesChristina Maier, Martin Clodi, Stephanie Neuhold, et al.
Heart (British Cardiac Society)|May 27, 2016
Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profilesRaphael Wurm, Michael Resl, Stephanie Neuhold, et al.
Cardiovascular Diabetology|February 3, 2021
Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitusSuriya Prausmüller, Michael Resl, Henrike Arfsten, et al.
British Journal of Clinical Pharmacology|June 30, 2020
Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failureHenrike Arfsten, Georg Goliasch, Philipp E Bartko, et al.
ESC Heart Failure|March 20, 2021
Neprilysin inhibition does not alter dynamic of proenkephalin-A 119-159 and pro-substance P in heart failureHenrike Arfsten, Georg Goliasch, Philipp E Bartko, et al.
European Heart Journal. Cardiovascular Imaging|July 2, 2019
Global regurgitant volume: approaching the critical mass in valvular-driven heart failurePhilipp E Bartko, Henrike Arfsten, Gregor Heitzinger, et al.
European Journal of Clinical Investigation|December 14, 2011
Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failureMax Plischke, Stephanie Neuhold, Christopher Adlbrecht, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
European Heart Journal|July 25, 2008
NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitusMartin Huelsmann, Stephanie Neuhold, Guido Strunk, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 30, 2022
Malnutrition outweighs the effect of the obesity paradoxSuriya Prausmüller, Gregor Heitzinger, Noemi Pavo, et al.
European Journal of Clinical Investigation|June 16, 2010
Electrical optimization of cardiac resynchronization in chronic heart failure is associated with improved clinical long-term outcomeChristopher Adlbrecht, Martin Hülsmann, Marianne Gwechenberger, et al.
Diabetes Care|July 1, 2009
Endothelial markers may link kidney function to cardiovascular events in type 2 diabetesChristina Maier, Martin Clodi, Stephanie Neuhold, et al.
Heart (British Cardiac Society)|May 27, 2016
Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profilesRaphael Wurm, Michael Resl, Stephanie Neuhold, et al.
Cardiovascular Diabetology|February 3, 2021
Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitusSuriya Prausmüller, Michael Resl, Henrike Arfsten, et al.
British Journal of Clinical Pharmacology|June 30, 2020
Increased concentrations of bioactive adrenomedullin subsequently to angiotensin-receptor/neprilysin-inhibitor treatment in chronic systolic heart failureHenrike Arfsten, Georg Goliasch, Philipp E Bartko, et al.
ESC Heart Failure|March 20, 2021
Neprilysin inhibition does not alter dynamic of proenkephalin-A 119-159 and pro-substance P in heart failureHenrike Arfsten, Georg Goliasch, Philipp E Bartko, et al.
European Heart Journal. Cardiovascular Imaging|July 2, 2019
Global regurgitant volume: approaching the critical mass in valvular-driven heart failurePhilipp E Bartko, Henrike Arfsten, Gregor Heitzinger, et al.
European Journal of Clinical Investigation|December 14, 2011
Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failureMax Plischke, Stephanie Neuhold, Christopher Adlbrecht, et al.
Pageof 8